{"id":"comparator-losartan","safety":{"commonSideEffects":[{"rate":"7-10","effect":"Dizziness"},{"rate":"3-5","effect":"Fatigue"},{"rate":"2-4","effect":"Hyperkalemia"},{"rate":"1-3","effect":"Cough"},{"rate":"1-2","effect":"Hypotension"},{"rate":"1-2","effect":"Renal impairment"}]},"_chembl":{"chemblId":"CHEMBL3983509","moleculeType":"Small molecule","molecularWeight":"434.92"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Losartan is an angiotensin II receptor blocker (ARB) that selectively antagonizes AT1 receptors in vascular smooth muscle and the adrenal gland. By blocking angiotensin II signaling, it causes vasodilation, reduces peripheral vascular resistance, and decreases aldosterone-mediated sodium and water retention, resulting in blood pressure reduction and improved renal protection.","oneSentence":"Losartan blocks angiotensin II type 1 (AT1) receptors, preventing vasoconstriction and aldosterone release to lower blood pressure.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:07:03.602Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypertension"},{"name":"Diabetic nephropathy in patients with type 2 diabetes"},{"name":"Heart failure with reduced ejection fraction"},{"name":"Post-myocardial infarction"}]},"trialDetails":[{"nctId":"NCT07262710","phase":"","title":"Association of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers With Post-Stroke Pneumonia: A Real-World Retrospective Cohort Study","status":"NOT_YET_RECRUITING","sponsor":"First Teaching Hospital of Tianjin University of Traditional Chinese Medicine","startDate":"2025-12-01","conditions":"Post-stroke Pneumonia","enrollment":13656},{"nctId":"NCT06831864","phase":"PHASE1","title":"Heart Failure With Reduced Ejection Fraction Polypill Implementation Strategy in Sri Lanka","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2025-02-15","conditions":"Heart Failure With Reduced Ejection Fraction","enrollment":40},{"nctId":"NCT00140907","phase":"PHASE4","title":"ALLOGRAFT, A Study to Evaluate the Renal Protective Effects of Losartan (0954-222)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2000-03-14","conditions":"High Blood Pressure","enrollment":367},{"nctId":"NCT00480805","phase":"PHASE3","title":"HYZAAR vs. Ramipril for Diabetes (0954A-245)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2001-08-08","conditions":"Type 2 Diabetes Mellitus, Hypertension","enrollment":312},{"nctId":"NCT00541684","phase":"PHASE3","title":"Health Assessment Study (0954-946)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2001-07-11","conditions":"Hypertension","enrollment":143},{"nctId":"NCT00140959","phase":"PHASE4","title":"Losartan and HCTZ and Amlodipine vs Atenolol and Amlodipine (0954A-309)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2003-02-01","conditions":"Hypertension","enrollment":120},{"nctId":"NCT00447603","phase":"PHASE3","title":"A Study of Losartan Compared to Losartan/HCTZ in Pediatric Patients With Hypertension (0954A-327)","status":"TERMINATED","sponsor":"Organon and Co","startDate":"2007-05-24","conditions":"Hypertension","enrollment":40},{"nctId":"NCT06431477","phase":"PHASE4","title":"Efficacy and Safety of Telmisartan Compared With Losartan","status":"RECRUITING","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2023-04-19","conditions":"Diabetic Nephropathies, Hypertension","enrollment":98},{"nctId":"NCT00568178","phase":"PHASE3","title":"An Extension Study Designed to Assess Effects of Losartan on Proteinuria in Pediatric Populations (MK-0954-326 AM1,EXT1(AM2))","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2007-06-01","conditions":"Proteinuria","enrollment":306},{"nctId":"NCT00496834","phase":"PHASE4","title":"LAAS (Losartan Anti-Atherosclerosis Study)(0954-330)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2008-02-01","conditions":"Hypertension","enrollment":201},{"nctId":"NCT01307046","phase":"PHASE3","title":"MK-0954A in Japanese Patients With Essential Hypertension Not Adequately Controlled With Losartan (MK-0954A-352)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2011-03-29","conditions":"Hypertension","enrollment":336},{"nctId":"NCT01307033","phase":"PHASE3","title":"A Long-term Study of the Safety of MK-0954A in Patients With Essential Hypertension (MK-0954A-351)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2011-03-29","conditions":"Hypertension","enrollment":278},{"nctId":"NCT00546754","phase":"PHASE3","title":"BP-EASE -Effectiveness of Losartan 50 mg/Hydrochlorothiazide (HCTZ) 12.5 mg Versus Valsartan 80 mg/HCTZ 12.5 mg Titrated as Needed in Patients With Essential Hypertension Not Controlled on Monotherapy (0954A-333)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2007-05-01","conditions":"Hypertension","enrollment":808},{"nctId":"NCT05843162","phase":"PHASE4","title":"A Clinical Trial to Evaluate the Blood Pressure Control of Telmisartan or Losartan in Essential Hypertensive Patients With Metabolic Syndrome","status":"UNKNOWN","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2023-06-01","conditions":"Essential Hypertension, Metabolic Syndrome","enrollment":116},{"nctId":"NCT03897868","phase":"PHASE2","title":"A Phase 2 Study to Assess Dose-response Relationship of HCP1803 in Patients With Essential Hypertension","status":"COMPLETED","sponsor":"Hanmi Pharmaceutical Company Limited","startDate":"2019-03-21","conditions":"Hypertension","enrollment":248},{"nctId":"NCT00140985","phase":"PHASE4","title":"Antiproteinuric Efficacy of Losartan Potassium in Patients With Non-Diabetic Proteinuric Renal Diseases (0954-213)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2000-02","conditions":"Renal Disorder","enrollment":97},{"nctId":"NCT00338260","phase":"PHASE3","title":"Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) Study (0954-133)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"1995-06","conditions":"Hypertension and Left Ventricular Hypertrophy (Thickening of the Main Pumping Chamber of the Heart)","enrollment":496},{"nctId":"NCT00092209","phase":"PHASE3","title":"Antihypertensive Efficacy and Safety of Approved Drugs in Japanese Patients With Essential Hypertension (Banyu Study)(0954A-302)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2002-04","conditions":"Hypertension","enrollment":840},{"nctId":"NCT00943852","phase":"PHASE1","title":"The Effect of Losartan and Losartan Plus Isosorbide Mononitrate on Central Blood Pressure Measurements (0954-317)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2006-08","conditions":"Hypertension","enrollment":13},{"nctId":"NCT00289887","phase":"PHASE3","title":"Obese Hypertension Study (0954-315)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2006-02","conditions":"Hypertension","enrollment":261},{"nctId":"NCT04238702","phase":"PHASE4","title":"Renohemodynamic Effects of Combined empagliflOzin and LosARtan","status":"COMPLETED","sponsor":"Amsterdam UMC, location VUmc","startDate":"2020-11-04","conditions":"Diabetes Mellitus, Type 2, Diabetic Kidney Disease","enrollment":24},{"nctId":"NCT04074551","phase":"PHASE3","title":"A Phase 3 Study to Compare the Efficacy and Safety of Co-administered HGP0608, HGP0904 and HCP1306 Versus HCP1701 in Patients With Hypertension and Dyslipidemia","status":"COMPLETED","sponsor":"Hanmi Pharmaceutical Company Limited","startDate":"2019-07-16","conditions":"Hypertension, Dyslipidemias","enrollment":145},{"nctId":"NCT01302691","phase":"PHASE3","title":"MK-0954E Study in Participants With Hypertension (MK-0954E-357)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-01-01","conditions":"Hypertension","enrollment":327},{"nctId":"NCT01033318","phase":"PHASE1","title":"A Study of the Pharmacokinetics and Pharmacodynamics of MK1809 (1809-001)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-09-11","conditions":"Hypertension","enrollment":30},{"nctId":"NCT02521246","phase":"PHASE3","title":"Efficacy and Safety of Candesartan Associated With Chlorthalidone Versus Losartan Associated With Hydrochlorothiazide (Hyzaar®) in Essential Hypertension Control","status":"WITHDRAWN","sponsor":"EMS","startDate":"2016-11","conditions":"Essential Arterial Hypertension","enrollment":""},{"nctId":"NCT02521233","phase":"PHASE3","title":"Efficacy and Safety of Candesartan Associated With Chlorthalidone in Essential Arterial Hypertension Control","status":"WITHDRAWN","sponsor":"EMS","startDate":"2016-11","conditions":"Essential Arterial Hypertension","enrollment":""},{"nctId":"NCT00856960","phase":"PHASE1","title":"The Effect of Hypertension Medications on Renal Blood Flow Measurements in Healthy Males (MK-0000-127)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2010-01","conditions":"Hypertension","enrollment":12},{"nctId":"NCT00886600","phase":"PHASE3","title":"A Study to Investigate the Magnitude and Duration of Response of MK0954 Compared to Placebo in Patients With Hypertension (0954-021)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"1991-05","conditions":"Hypertension","enrollment":122},{"nctId":"NCT00949884","phase":"PHASE4","title":"Olmesartan Comparison to Losartan in Hypertensive Subjects","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2009-08","conditions":"Hypertension","enrollment":941},{"nctId":"NCT00617877","phase":"NA","title":"Antihypertensive Response to Losartan and Genetic Polymorphisms","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2005-03","conditions":"Hypertension","enrollment":800},{"nctId":"NCT00887250","phase":"PHASE3","title":"A Study to Investigate the Antihypertensive Efficacy of MK0954","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"1991-12","conditions":"Hypertension","enrollment":366},{"nctId":"NCT00888355","phase":"PHASE3","title":"MK0954 Versus Placebo for Treatment of Mild to Moderate Hypertension","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"1992-05","conditions":"Hypertension","enrollment":428}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["MK0954","Losartan"],"phase":"phase_3","status":"active","brandName":"Comparator: Losartan","genericName":"Comparator: Losartan","companyName":"Merck Sharp & Dohme LLC","companyId":"merck-sharp-dohme-llc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Losartan blocks angiotensin II type 1 (AT1) receptors, preventing vasoconstriction and aldosterone release to lower blood pressure. Used for Hypertension, Diabetic nephropathy in patients with type 2 diabetes, Heart failure with reduced ejection fraction.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}